Formulation, Development and Evaluation of Budesonide Oral Nano-sponges Using DOE Approach: In-vivo Evidences
Authors:
Open Access
- 5 August 2020
- journal article
- research article
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 11 (2) , 286-294
Abstract
Purpose: The prevalent types of idiopathic inflammatory bowel disease are ulcerative colitis (UC) and Crohn’s disease, which affects a large number of populations. Budesonide (BUD) is a glucocorticoid with potent anti-inflammatory activity but low systemic efficacy because of high receptor affinity and rapid diversion. To overcome low efficacy and availability, a novel BUD nano-sponges was formulated using quasi- solvent diffusion and Eudragit S-100 as polymer. It was then investigated for the effect of process variables using Box-Behnken design.Keywords
This publication has 27 references indexed in Scilit:
- Murine Models of Inflammatory Bowel Disease (IBD)Toxicologic Pathology, 2013
- Oral administration of the flavonoid myricitrin prevents dextran sulfate sodium-induced experimental colitis in mice through modulation of PI3K/Akt signaling pathwayMolecular Nutrition & Food Research, 2013
- N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in ratsInternational Journal of Pharmaceutics, 2011
- Zeta Potential Measurement2010
- Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanospongesDrug Delivery, 2010
- Microsponges: A novel strategy for drug delivery systemJournal of Advanced Pharmaceutical Technology & Research, 2010
- Treatment of inflammatory bowel disease: A review of medical therapyWorld Journal of Gastroenterology, 2008
- Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitisNature Clinical Practice Gastroenterology & Hepatology, 2006
- Topical delivery of therapeutic agents in the treatment of inflammatory bowel diseaseAdvanced Drug Delivery Reviews, 2005
- Crohn's diseaseThe Lancet, 2002